MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

52.608

87.826

EPS

0.4

Dividendrendement

0.29

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.47% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.26%

Volgende Winsten

30 jan 2026

Volgende dividenddatum

6 feb 2026

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

569M

12B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jan 2026, 22:18 UTC

Marktinformatie

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 jan 2026, 21:43 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 jan 2026, 20:39 UTC

Marktinformatie

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 jan 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 jan 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 jan 2026, 20:30 UTC

Marktinformatie

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 jan 2026, 20:15 UTC

Marktinformatie

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 jan 2026, 19:58 UTC

Acquisities, Fusies, Overnames

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 jan 2026, 19:42 UTC

Marktinformatie

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 jan 2026, 19:38 UTC

Acquisities, Fusies, Overnames

Wolters Kluwer Acquires StandardFusion >WTKWY

9 jan 2026, 19:31 UTC

Winsten

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 jan 2026, 19:28 UTC

Winsten

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 jan 2026, 18:30 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 jan 2026, 18:23 UTC

Marktinformatie

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 17:19 UTC

Marktinformatie

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jan 2026, 17:07 UTC

Marktinformatie

McDonald's Promotions Appear Successful -- Market Talk

9 jan 2026, 17:06 UTC

Marktinformatie

Oil Futures on Track for Weekly Gains -- Market Talk

9 jan 2026, 17:05 UTC

Winsten

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 jan 2026, 16:57 UTC

Marktinformatie

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

11.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 113.38 USD  11.47%

Hoogste 123 USD

Laagste 105 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat